Glutamic acid diethyl ester induces catalepsy in rats. A new model for schizophrenia?

doi:10.1016/0304-3940(82)90196-3

Neuroscience Letters

Volume 34, Issue 3, 31 December 1982, Pages 325-329

https://doi.org/10.1016/0304-3940(82)90196-3 Get rights and content

Abstract

The glutamate antagonist glutamic acid diethyl ester is found to produce catalepsy in rats, when administered into the lateral ventricle. Since the cerebrospinal fluid content of glutamate is reduced in patients with schizophrenia, the central effects of glutamate antagonists are a possible experimental model for schizophrenia.

References (17)

W.J. Freed et al.
Glutamic acid and ethanol dependence
Pharmacol. Biochem. Behav.
(1978)
W.J. Freed et al.
Impairment of instrumental learning in rats by glutamic acid diethyl ester
Pharmacol. Biochem. Behav.
(1981)
J.S. Kim et al.
Effect of frontal cortex ablation on striatal glutamic acid level in rat
Brain Res.
(1977)
J.S. Kim et al.
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Neurosci. Lett.
(1980)
E.P. Noble et al.
A simple and rapid method for injecting H³-norepinephrine into the lateral ventricle of the rat brain
Life Sci.
(1967)
T.L. Perry
Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction
Neurosci., Lett.
(1982)
H.J. Spencer
Antagonism of cortical excitation of striatal neurons by glutamic acid diethyl ester: evidence for glutamic acid as an excitatory transmitter in the rat striatum
Brain Res.
(1976)
C.J. Carter
Glutamatergic pathways from the medial prefrontal cortex to the anterior striatum, nucleus accumbens and substantia nigra
Brit. J. Pharmacol.
(1980)

There are more references available in the full text version of this article.

Cited by (8)

Aspects of Piaget's cognitive developmental psychology and neurobiology of psychotic disorders - An integrative model
2008, Medical Hypotheses
Psychological, neurobiological and neurodevelopmental approaches have frequently been used to provide pathogenic concepts on psychotic disorders. However, aspects of cognitive developmental psychology have hardly been considered in current models. Using a hypothesis-generating approach an integration of these concepts was conducted. According to Piaget (1896–1980), assimilation and accommodation as forms of maintenance and modification of cognitive schemata represent fundamental processes of the brain. In general, based on the perceived input stimuli, cognitive schemata are developed resulting in a conception of the world, the realistic validity and the actuality of which is still being controlled and modified by cognitive adjustment processes. In psychotic disorders, however, a disproportion of environmental demands and the ability to activate required neuronal adaptation processes occurs. We therefore hypothesize a failure of the adjustment of real and requested output patterns. As a consequence autonomous cognitive schemata are generated, which fail to adjust with reality resulting in psychotic symptomatology. Neurobiological, especially neuromodulatory and neuroplastic processes play a central role in these perceptive and cognitive processes. In conclusion, integration of cognitive developmental psychology into the existing pathogenic concepts of psychotic disorders leads to interesting insights into basic disease mechanisms and also guides future research in the cognitive neuroscience of such disorders.
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: Possible implications for the treatment of psychiatric disorders
1996, Life Sciences
Sigma (σ) receptors, improperly classified as belonging to the opiate receptor family when discovered in 1976, were subsequently confused with phencyclidine binding sites for several years. It's only recently, with the emergence of new selective ligands that their functional significance could be meaningfully addressed. Several subtypes of σ receptors are present in high densities in the limbic structures as well as in motor-related areas of the CNS. Different lines of evidence suggest that a major role for σ receptors might be to regulate the activity of the gluTamatergic system via the modulation one of its subtype of receptor, the NMDA receptor. This modulation of the gluTamatergic system could in turn interfere with the dopaminergic neurotransmission with which, however, σ ligands could also interact directly.
The potential involvement of σ receptors in schizophrenia has been considered ever since their discovery. The initial suggestion to this respect emerged from the observation that several of the earliest σ ligands induced psychotomimetic symptoms such as delusions, hallucinations and depersonalization. This link was later reinforced with the demonstration that several neuroleptics, such as haloperidol, have a high affinity for σ receptors, whereas, some new molecules with a high affinity for σ receptors, but a low affinity for dopaminergic receptors demonstrated a “neuroleptic-like” pharmacological profile. However, the therapeutic efficacy of selective σ ligands in schizophrenia has not yet been established and it has even been suggested that σ receptors might be responsible for some side effects of the classical neuroleptics. The possible implication of σ receptors in affective disorders has also been suggested by reports showing that some antidepressant drugs have a high affinity for σ receptors and that long-term treatments with antidepressant drugs, even with those devoid of affinity for σ receptors, modify their binding characteristics.
In conclusion, indirect evidence suggests possible etiological and/or therapeutic roles for σ receptors in some psychiatric disorders. However, despite several attempts, no clear indication of a therapeutic efficacy of σ ligands has yet emerged. More selective ligands and fundamental studies on the respective role of the different subtypes of σ receptors are needed before clear concepts can be formulated.
Presynaptic dopaminergic modulation of cortical input to the striatum
1986, Life Sciences
2-Amino-4-phosphonobutyric acid selectively blocks two-way avoidance learning in the mouse
1985, Neuroscience Letters
There seems to be ample evidence supporting the view that glutamate plays a significant role in the mammalian brain as a neurotransmitter. It is considered to be a likely transmitter candidate in one or more hippocampal pathways [25]. Recently it has been visualized in excitatory, possibly glutamatergic, neurons in the hippocampus [26]. Glutamate has been proposed to mediate memory formation [2, 15, 27]. We wanted to see if blocking glutamate action by a specific glutamate antagonist could result in reduction of learning ability. 2-Amino-4-phosphonobutyric acid (APB) is an analogue of glutamic acid and has been used as a glutamate antagonist in electrophysiological studies on invertebrate neuromuscular junction [7], retina [16, 23, 24] and hippocampus [10, 30]. We tested the influence of APB on the acquisition of two way avoidance learning in the shuttle box and on learning in the water maze. Our results show that intraperitoneal injection of APB led to a reduction in avoidance learning, whereas learning in the water maze was unaffected.
Acidic amino acid binding sites in mammalian neuronal membranes: their characteristics and relationship to synaptic receptors
1984, Brain Research Reviews
This review summarizes studies designed to label and characterize mammalian synaptic receptors for glutamate, aspartate and related acidic amino acids using in vitro ligand binding techniques. The binding properties of the 3 major ligands employed — l-[³H]glutamate, l-[³H] aspartate and [³H]kainate —are described in terms of their kinetics, the influence of ions, pharmacology, molecular nature, localization and physiological/pharmacological function. In addition, the binding characteristics are described of some new radioligands — [³H]AMPA, l-[³H]cysteine sulphinate, l-[³⁵S]cysteate, d-[³H]as-partate, d,l-[³H]APB, d-[³H]APV and d,l-[³H]APH. Special emphasis is placed on recent findings which allow a unification of the existing binding data, and detailed comparisons are made between binding site characteristics and the known properties of the physiological/pharmacological receptors for acidic amino acids. Through these considerations, a binding site classification is suggested which differentiates 5 different sites. Four of the binding site subtypes are proposed to correspond to the individual receptor classes identified in electrophysiological experiments; thus, A1 = NMDA receptors; A2 = quis-qualate receptors; A3 = kainate receptors; $A 4 = l - APB receptors$ ; the fifth site is proposed to be the recognition site for a Na⁺-dependent acidic amino acid membrane transport process. An evaluation of investigations designed to elucidate regulatory mechanisms at acidic amino acid binding sites is made; hypotheses such as the Ca²⁺-activated protease hypothesis of long-term potentiation are assessed in terms of the new binding site/receptor classification scheme, and experiments are suggested which will clarify and expand this exciting area in the future.
The Catalepsy Test: Its Ups and Downs
1988, Behavioral Neuroscience

View all citing articles on Scopus

View full text

Glutamic acid diethyl ester induces catalepsy in rats. A new model for schizophrenia?

Abstract

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Brain Res.

Neurosci. Lett.

Life Sci.

Neurosci., Lett.

Brain Res.

Glutamatergic pathways from the medial prefrontal cortex to the anterior striatum, nucleus accumbens and substantia nigra

Brit. J. Pharmacol.